



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

MKRAWZSENEK@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3020

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

February 13, 2004

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

February 13, 2004

Date


Michael R. Krawzenek

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/611,803 entitled "PHARMACEUTICAL DOSAGE FORM BEARING PREGNANCY-FRIENDLY INDICIA" – Éric Gervais et al.*
Our reference: GOUD:031US
Client reference: AML/11621.35

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references A1-A8, B1-B9 and C10-C12.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:031US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Michael R. Krawzenek
Reg. No. 51,898

MRK/kmv
Encl.: as noted

25384776.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:
Eric Gervais *et al.*

Serial No.: 10/611,803

Filed: July 1, 2003

For: PHARMACEUTICAL DOSAGE FORM
BEARING PREGNANCY-FRIENDLY
INDICIA

Group Art Unit: 1615

Examiner: Unknown

Atty. Dkt. No.: GOUD:031US

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
February 13, 2004	
Date	Michael R. Krawzenek

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:031US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Michael R. Krawzenek
Reg. No. 51,898
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 13, 2004

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

GOUD:031US

10/611,803

Applicant

Eric Gervais *et al.*

Filing Date:

July 1, 2003

Group:

1615

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,778,984	12/06/88	Marsik	128	738	1/30/87
	A2	5,443,288	8/22/95	Miles	283	2	7/25/94
	A3	5,457,895	10/17/95	Thompson <i>et al.</i>	34	296	10/01/93
	A4	5,531,230	7/02/96	Bell	128	842	7/14/95
	A5	5,836,890	11/17/98	Jackson	600	551	5/30/97
	A6	6,223,559	5/01/01	Coleman	63	1.13	7/20/99
	A7	6,226,564	5/01/01	Stuart	700	231	11/01/96
	A8	6,340,695	1/22/02	Gervais	514	345	6/21/01

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	2,050,054	3/20/92	Canada			
	B2	2,078,578	2/05/02	Canada			
	B3	2,081,679	5/28/93	Canada			
	B4	2,280,279	2/14/00	Canada			
	B5	2,310,069	6/03/99	Canada			
	B6	2,321,991	9/02/99	Canada			
	B7	EP 1 149 572	10/31/01	Europe			
	B8	WO 2004/004694	1/15/04	PCT			
	B9	WO 97/48384	12/24/97	PCT			

25384711.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

GOUD:031US

10/611,803

Applicant

Eric Gervais *et al.*

Filing Date:

July 1, 2003

Group:

1615

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Bishai <i>et al.</i> , "The efficacy and safety of Diclectin (R) (doxylamine/pyridoxine) for nausea and vomiting of pregnancy," <i>Today's Therapeutic Trends</i> , 17(2):167-179, 1999.
	C11	Muno, "Broadening utility of tablet and capsule imprints," <i>Journal of Pharmacy Practice</i> , 13(2):130-140, 2000.
	C12	Pedersen, "Tablet tooling: design, maintenance and troubleshooting," <i>Pharmaceutical Technology Europe</i> , 11(2):22-28, 1999.

25384711.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.